SCHEMBL9949997

SCHEMBL9949997

CCC1CCC(Cc2cccc(C3OCCO3)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
HTR1A P08908 2/20 0.33
SLC6A4 P31645 1/20 0.33
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GBA1 P04062 1/20 0.33
DRD3 P35462 3/20 0.32
EED O75530 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
DRD2 P14416 2/20 0.32
DRD1 P21728 1/20 0.32
DRD4 P21917 1/20 0.32
DRD5 P21918 1/20 0.32
KCNH2 Q12809 1/20 0.31
IDO1 P14902 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949723 0.89 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1HTTHTR1ASLC6A4
SCHEMBL9950597 0.88 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1HTTHTR1ASLC6A4
SCHEMBL9949579 0.86 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1HTTLMNADRD3
SCHEMBL9949911 0.86 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1HTTDRD3DRD2
SCHEMBL9949859 0.85 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1HTTLMNANPSR1
SCHEMBL9949782 0.81 GBA1 (0.33) SMN1; SMN2ALDH1A1HTTSLC6A4GBA1
SCHEMBL9950310 0.80 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1HTTLMNADRD3
SCHEMBL11941052 0.79 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1HTTSLC6A4LMNA
SCHEMBL9951498 0.79 CHRNA7 (0.37) SMN1; SMN2ALDH1A1HTTDRD3EED
SCHEMBL9950538 0.78 EED (0.37) SMN1; SMN2ALDH1A1HTTLMNAEED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748078-B2 Cyclic compound, process for preparation thereof, radiation-sensitive composition, and method for formation of resist pattern MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2014-06-10 US disclosed
EP-2476662-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN Mitsubishi Gas Chemical Company, Inc. (JP) 2012-07-18 EP disclosed
US-20120164576-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120164576-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN RAD1, RER1, REV1 SMN1; SMN2 1855/4885ALDH1A1 1204/4885HTT 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.